Erratum: Targeting Vascular Endothelial-Cadherin in Tumor-Associated Blood Vessels Promotes T-cell-Mediated Immunotherapy (Cancer Res (2018) 78:19 (5718)DOI: 10.1158/0008-5472.CAN-16-3129);Targeting vascular endothelial-cadherin in tumor-associated blood vessels promotes T-cell–mediated immunotherapy

Cancer Research

Volumn 77, Issue 16, 2017, Pages 4434-4447

  Zhao, Yang ^a   Ting, Ka Ka ^a   Li, Jia ^a   Cogger, Victoria C ^a   Chen, Jinbiao ^a   Johansson Percival, Anna ^b   Ngiow, Shin Foong ^c   Holst, Jeff ^a   Grau, Georges ^d   Goel, Shom ^e   Muller, Thorleif ^f   Dejana, Elisabetta ^g   McCaughan, Geoff ^a   Smyth, Mark J ^c   Ganss, Ruth ^b   Vadas, Mathew A ^a   Gamble, Jennifer R ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

^e DANA FARBER CANCER INSTITUTE   (United States)

^f Mirrx Therapeutics A S   (Denmark)

^g FIRC INSTITUTE OF MOLECULAR ONCOLOGY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN RECEPTOR; CD5-2; MICRORNA; MICRORNA 27A; MONOCLONAL ANTIBODY; OLIGONUCLEOTIDE; PROGRAMMED DEATH 1 RECEPTOR; RMP1-14; UNCLASSIFIED DRUG; VASCULAR ENDOTHELIAL CADHERIN; CADHERIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CELL INFILTRATION; CELLULAR DISTRIBUTION; COLON CANCER; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; ENDOTHELIUM; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN RNA BINDING; SINGLE DRUG DOSE; TIGHT JUNCTION; TUMOR VASCULARIZATION; ANIMAL; COLONIC NEOPLASMS; IMMUNOLOGY; IMMUNOTHERAPY; MELANOMA, EXPERIMENTAL; MOLECULARLY TARGETED THERAPY; PROCEDURES; T LYMPHOCYTE; UMBILICAL VEIN ENDOTHELIAL CELL; VASCULAR ENDOTHELIUM; VASCULARIZATION;

ANIMALS; CADHERINS; COLONIC NEOPLASMS; ENDOTHELIUM, VASCULAR; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; IMMUNOTHERAPY; MELANOMA, EXPERIMENTAL; MICE; MOLECULAR TARGETED THERAPY; T-LYMPHOCYTES;

EID: 85028343560     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-18-2028     Document Type: Erratum

References (50)

1. Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med 2013;19:1423–37.
2. Jain RK. Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. J Clin Oncol 2013;31:2205–18.
3. Ackerman D, Simon MC. Hypoxia, lipids, and cancer: surviving the harsh tumor microenvironment. Trends Cell Biol 2014;24:472–8.
4. Tredan O, Galmarini CM, Patel K, Tannock IF. Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst 2007;99:1441–54.
5. Goel S, Duda DG, Xu L, Munn LL, Boucher Y, Fukumura D, et al. Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev 2011;91:1071–121.
6. Dvorak HF. Vascular permeability to plasma, plasma proteins, and cells: an update. Curr Opin Hematol 2010;17:225–9.
7. Huang YH, Yuan JP, Righi E, Kamoun WS, Ancukiewicz M, Nezivar J, et al. Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc Natl Acad Sci U S A 2012;109:17561–6.
8. Hamzah J, Jugold M, Kiessling F, Rigby P, Manzur M, Marti HH, et al. Vascular normalization in Rgs5-deficient tumours promotes immune destruction. Nature 2008;453:410–4.
9. Neumann AK, Yang J, Biju MP, Joseph SK, Johnson RS, Haase VH, et al. Hypoxia inducible factor 1 alpha regulates T cell receptor signal transduction. Proc Natl Acad Sci U S A 2005;102:17071–6.
10. Gentles AJ, Newman AM, Liu CL, Bratman SV, Feng W, Kim D, et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat Med 2015;21:938–45.
11. Jain RK. Lessons from multidisciplinary translational trials on anti-angiogenic therapy of cancer. Nat Rev Cancer 2008;8:309–16.
12. Huang Y, Goel S, Duda DG, Fukumura D, Jain RK. Vascular normalization as an emerging strategy to enhance cancer immunotherapy. Cancer Res 2013;73:2943–8.
13. Mazzone M, Dettori D, Leite de Oliveira R, Loges S, Schmidt T, Jonckx B, et al. Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization. Cell 2009;136:839–51.
14. Magrini E, Villa A, Angiolini F, Doni A, Mazzarol G, Rudini N, et al. Endothelial deficiency of L1 reduces tumor angiogenesis and promotes vessel normalization. J Clin Invest 2014;124:4335–50.
15. Dejana E, Orsenigo F, Lampugnani MG. The role of adherens junctions and VE-cadherin in the control of vascular permeability. J Cell Sci 2008; 121:2115–22.
16. Dejana E. Endothelial cell-cell junctions: happy together. Nat Rev Mol Cell Biol 2004;5:261–70.
17. Lampugnani MG, Orsenigo F, Gagliani MC, Tacchetti C, Dejana E. Vascular endothelial cadherin controls VEGFR-2 internalization and signaling from intracellular compartments. J Cell Biol 2006;174:593–604.
18. Shen J, Frye M, Lee BL, Reinardy JL, McClung JM, Ding K, et al. Targeting VE-PTP activates TIE2 and stabilizes the ocular vasculature. J Clin Invest 2014;124:4564–76.
19. Taddei A, Giampietro C, Conti A, Orsenigo F, Breviario F, Pirazzoli V, et al. Endothelial adherens junctions control tight junctions by VE-cadherin-mediated upregulation of claudin-5. Nat Cell Biol 2008;10:923–34.
20. Carmeliet P, Lampugnani MG, Moons L, Breviario F, Compernolle V, Bono F, et al. Targeted deficiency or cytosolic truncation of the VE-cadherin gene in mice impairs VEGF-mediated endothelial survival and angiogenesis. Cell 1999;98:147–57.
21. Flemming S, Burkard N, Renschler M, Vielmuth F, Meir M, Schick MA, et al. Soluble VE-cadherin is involved in endothelial barrier breakdown in systemic inflammation and sepsis. Cardiovasc Res 2015;107:32–44.
22. Zanetta L, Corada M, Grazia Lampugnani M, Zanetti A, Breviario F, Moons L, et al. Downregulation of vascular endothelial-cadherin expression is associated with an increase in vascular tumor growth and hemorrhagic complications. Thromb Haemost 2005;93:1041–6.
23. Chhabra R, Dubey R, Saini N. Cooperative and individualistic functions of the microRNAs in the miR-23a-27a-24–2 cluster and its implication in human diseases. Mol Cancer 2010;9:232.
24. Huang S, He X, Ding J, Liang L, Zhao Y, Zhang Z, et al. Upregulation of miR-23a approximately 27a approximately 24 decreases transforming growth factor-beta-induced tumor-suppressive activities in human hepatocellular carcinoma cells. Int J Cancer 2008;123:972–8.
25. Zhou L, Liang X, Zhang LL, Yang LY, Nagao N, Wu H, et al. MiR-27a-3p functions as an oncogene in gastric cancer by targeting BTG2. Oncotarget 2016;7:1–12.
26. Young JA, Ting KK, Li J, Moller T, Dunn L, Lu Y, et al. Regulation of vascular leak and recovery from ischemic injury by general and VE-cadherin-restricted miRNA antagonists of miR-27. Blood 2013;122:2911–9.
27. Cogger V, Reilly J, Warren A, Couteur D. A standardized method for the analysis of liver sinusoidal endothelial cells and their fenestrations by scanning electron microscopy. J Vis Exp 2015;e52698. doi: 10.3791/52698.
28. Tyagi N, Roberts AM, Dean WL, Tyagi SC, Lominadze D. Fibrinogen induces endothelial cell permeability. Mol Cell Biochem 2008;307:13–22.
29. Ngiow SF, Young A, Jacquelot N, Yamazaki T, Enot D, Zitvogel L, et al. A threshold level of intratumor CD8þ T-cell PD1 expression dictates therapeutic response to anti-PD1. Cancer Res 2015;75:3800–11.
30. Arina A, Idel C, Hyjek EM, Alegre ML, Wang Y, Bindokas VP, et al. Tumor-associated fibroblasts predominantly come from local and not circulating precursors. PNAS 2016;113:7551–6.
31. Wessel F, Winderlich M, Holm M, Frye M, Rivera-Galdos R, Vockel M, et al. Leukocyte extravasation and vascular permeability are each controlled in vivo by different tyrosine residues of VE-cadherin. Nat Immunol 2014;15:223–30.
32. Li X, Stankovic M, Lee BP, Aurrand-Lions M, Hahn CN, Lu Y, et al. JAM-C induces endothelial cell permeability through its association and regulation of {beta}3 integrins. Arterioscler Thromb Vasc Biol 2009;29:1200–6.
33. Brindle NP, Saharinen P, Alitalo K. Signaling and functions of angiopoie-tin-1 in vascular protection. Circ Res 2006;98:1014–23.
34. June CH. Adoptive T cell therapy for cancer in the clinic. J Clin Invest 2007;117:1466–76.
35. Terme M, Colussi O, Marcheteau E, Tanchot C, Tartour E, Taieb J. Modulation of immunity by antiangiogenic molecules in cancer. Clin Dev Immunol 2012;2012:1–8.
36. Dirkx AEM. Anti-angiogenesis therapy can overcome endothelial cell anergy and promote leukocyte-endothelium interactions and infiltration in tumors. FASEB J 2006;20:621–30.
37. Zhang Y, Ertl HC. Starved and asphyxiated: how can CD8(þ) T cells within a tumor microenvironment prevent tumor progression. Front Immunol 2016;7:32.
38. Swartz MA, Lund AW. Lymphatic and interstitial flow in the tumour microenvironment: linking mechanobiology with immunity. Nat Rev Cancer 2012;12:210–9.
39. Muller WA. Leukocyte–endothelial-cell interactions in leukocyte transmigration and the inflammatory response. Trends Immunol 2003;24:326–33.
40. Middleton J, Patterson A, Gardner L, Schmutz C, Ashton B. Leukocyte extravasation: chemokine transport and presentation by the endothelium. Blood 2002;100:3853–60.
41. Dustin M. Role of adhesion molecules in activation signaling in T lymphocytes. J Clin Immunol 2001;21:258–63.
42. Gamble J, Drew J, Trezise L, Underwood A, Parsons M, Kasminkas L, et al. Angiopoietin-1 is an antipermeability and anti-inflammatory agent in vitro and targets cell junctions. Circ Res 2000;87:603–7.
43. Asahara T, Chen DH, Takahashi T, Fujakawa K, Kearney M, Magner M, et al. Tie2 receptor ligands, angiopoietin-1 and angiopoietin-2, modulate VEGF-induced postnatal neovascularization. Circ Res 1998;83:233–40.
44. Frye M, Dierkes M, Kuppers V, Vockel M, Tomm J, Zeuschner D, et al. Interfering with VE-PTP stabilizes endothelial junctions in vivo via Tie-2 in the absence of VE-cadherin. J Exp Med 2015;212:2267–87.
45. Mazzieri R, Pucci F, Moi D, Zonari E, Ranghetti A, Berti A, et al. Targeting the ANG2/TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells. Cancer Cell 2011;19:512–26.
46. Nair S, Boczkowski D, Moeller B, Dewhirst M, Vieweg J, Gilboa E. Synergy between tumor immunotherapy and antiangiogenic therapy. Blood 2003;102:964–71.
47. Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Vinals F, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009;15:220–31.
48. Vickers AJ. Prediction models: revolutionary in principle, but do they do more good than harm? J Clin Oncol 2011;29:2951–2.
49. Stockmann C, Doedens A, Weidemann A, Zhang N, Takeda N, Greenberg JI, et al. Deletion of vascular endothelial growth factor in myeloid cells accelerates tumorigenesis. Nature 2008;456:814–8.
50. Ai M, Budhani P, Sheng J, Balasubramanyam S, Bartkowiak T, Jaiswal AR, et al. Tumor hypoxia drives immune suppression and immunotherapy resistance. J ImmunoTher Cancer 2015;3:P392.